Mayo Clinic Tests Cerebrospinal Fluid DNA to Diagnose Unclear Brain Tumors

Why Fluid Testing Matters When Biopsy Is Risky

Mayo Clinic researchers in Rochester, Minnesota, and Phoenix, Arizona, published a study in the Journal of Neuro-Oncology. The team analyzed DNA found in cerebrospinal fluid from 76 patients. This method offers a diagnostic alternative when MRI scans are inconclusive or biopsies are too risky.

The study focused on cases where standard imaging failed to confirm a tumor type. Researchers collected fluid samples and sequenced the genetic material. This approach helps identify specific mutations that point to particular tumor subtypes.

Doctors often rely on MRI to locate tumors. However, some lesions appear ambiguous on scans. A biopsy provides tissue but carries bleeding or infection risks. Cerebrospinal fluid testing avoids these surgical dangers. It offers a minimally invasive way to gather genetic data.

What Does This Mean for Patient Care?

The technique detects tumor-specific DNA fragments floating in the fluid. These fragments act as molecular fingerprints. They reveal which tumor type is present without cutting into the brain. This is crucial for patients with tumors in delicate areas.

This method could change how clinicians handle diagnostic uncertainty. It provides data when other tools fall short. Patients may receive more accurate diagnoses faster. Accurate diagnosis leads to better treatment plans.

The study highlights a growing trend in liquid biopsies. Researchers hope this approach becomes standard for unclear brain tumor cases. It reduces the need for risky procedures. Patients gain clearer answers with less physical risk.

Frequently Asked Questions

Is cerebrospinal fluid testing safer than a brain biopsy? Yes, it avoids surgical incisions. The procedure involves a lumbar puncture, which is less invasive than craniotomy or stereotactic biopsy.

Can this test replace MRI scans? No, it complements MRI. MRI locates the tumor, while fluid testing identifies the tumor type through DNA analysis.

How many patients were included in the study? The study analyzed samples from 76 patients. This cohort was selected for diagnostic uncertainty in their brain tumor cases.